



3.4.6 Diagnosis and Treatment of Allergic Diseases



Publications: 55 | **Q1:**34

COMPOSITION

Santiago Eugenio Quirce Gancedo.

Jefe de Servicio de Alergología. Hospital Universitario La Paz

- **María Pilar Encarnación Barranco Sanz.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **María Teresa Caballero Molina.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **María Luisa Caballero Soto.** Facultativo Especialista de Área en Farmacia hospitalaria. Hospital Universitario La Paz
- **Francisco Javier Contreras Porta.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **Leticia de las Vecillas Sánchez.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **Francisco Javier Domínguez Ortega.** Jefe de Sección de Alergología. Hospital Universitario La Paz

- **Ana Fiandor Román.** Jefe de Sección de Alergología. Hospital Universitario La Paz
- **Carmen Gómez Traseira.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **Juan Alberto Luna Porta.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **María Magdalena Lluch Bernal.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **María Pedrosa Delgado.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **Elsa Phillips Angles.** Facultativo Especialista de Área en Alergología Pediátrica. Hospital Universitario La Paz
- **Mónica Rodríguez Álvarez.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **María Rosa Rodríguez Pérez.** Investigadora Senior. Contrato Miguel Servet (I2). Hospital Universitario La Paz
- **Margarita Tomás Pérez.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **Ana María Umpiérrez Rodríguez.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

STRATEGIC OBJETIVES

- These group members are specialists in various areas of allergic diseases, which enable them to perform clinical studies and basic research on the main allergic diseases (food allergies, asthma and rhinitis, urticaria/ angioedema and drug allergies). The group's strategic research objectives include:
 - The development of new techniques to improve the diagnosis of food allergies by determining the molecular sensitisation profile
 - The study of hyperresponsiveness and airway inflammation in asthma, as well as the role of allergen exposure and comorbidities in this disease
 - The study of the pathogenesis and treatment of eosinophilic diseases of the airways (asthma, eosinophilic bronchitis) and the gastrointestinal tract (eosinophilic oesophagitis)
 - The characterisation of various types of angioedema caused by Bradykinin (hereditary and acquired) and improvements in their diagnosis and treatment
 - Research on the epidemiology and pathomechanisms of severe adverse reactions caused by immune hypersensitivity reactions to drugs

RESEARCH LINES

- Food allergy (milk, egg, fruit, cereals): molecular diagnosis (by allergenic components) and treatment with oral desensitisation
- Epidemiology, physiopathology, diagnosis and treatment of angioedema and urticaria
- Studies on bronchial hyperresponsiveness to direct and indirect agents and airway inflammation
- Eosinophilic diseases of the respiratory tract (eosinophilic bronchitis) and digestive system (eosinophilic esophagitis)
- Persistent and difficult to control asthma: study on the influence of common and occupational allergens, comorbidities and new therapies
- Aspirin-exacerbated respiratory disease (AERD): inflammatory markers and desensitisation protocol
- Adverse immunologic reactions to drugs: study on the cellular and molecular mechanisms involved.
- Identification and characterization of new environmental allergens and modulating factors of allergenicity.



3.4 Large System Pathologies Area

RESEARCH ACTIVITY

Doctoral theses

- **Marques Mejías MA.** Broncoespasmo y urticaria aguda en el departamento de urgencias pediátricas: características, manejo e impacto de los factores ambientales [dissertation]. *Madrid: UAM: 2023(19/01/2023). Director: Quirce Gancedo SE.*

Publications

- **Adnan A, Acharya S, Alenazy LA, de las Vecillas L, Bianchi PG, Picard M, Calbache-Gil L, Romero-Pinedo S, Abadia-Molina AC, Kerr W, Pedicone C, Nagai J, Hollers E, Dwyer D, Castells M.** Multistep IgE mast cell desensitization is a dose- and time-dependent process partially regulated by SHIP-1. *J Immunol.* 2023; 210(6): 709-20. Article. IF: 3.6; Q2
- **Américo DA, Colás C, Dávila , Del Cuvillo A, Romero JD, Domínguez-Ortega J, Presa IJ, Sastre ML, Lacomba JM, Sala-Cunill A, Sánchez-García S, Pérez BV, Vidal C, Santiago ALV.** ALERGODATA: sentinel registry of health outcomes in allergic patients treated with biological therapies at specialized allergology clinics in Spain. *J Invest Allerg Clin.* 2023; 33(6): 479-82. Article. IF: 6.1; Q1
- **Annesi-Maesano I, Cecchi L, Biagioni B, Chung KF, Clot B, Coen MC, Amato GD, Damialis A, Domínguez-Ortega J, Galán C, Gilles S, Holgate S, Jeebhay M, Kazadzis S, Papadopoulos NG, Quirce S, Sastre J, Tummon F, Traidl-Hoffmann C, Walusiak-Skorupa J, Alonso-Coello P, Canelo-Aybar C, Cantero-Foriz Y, Rigau D, Salazar J, Verdugo-Paiva F, Jutel M, Akdis CA, Agache I.** Is exposure to pollen a risk factor for moderate and severe asthma exacerbations? *Allergy.* 2023; 78(8): 2121-47. Review. IF: 12.6; D1
- **Arismendi E, Cisneros C, Blanco-Aparicio M, Martínez-Moragón E, Quirce S, Conejero DB, López-Moure A, Sánchez-Herrero MG.** REDES Study: Mepolizumab is effective in patients with severe asthma and comorbid nasal polyps. *J Invest Allerg Clin.* 2023; 33(6): 476-79. Editorial Material. IF: 6.1; Q1
- **Barroso B, Valverde-Monge M, Alobid , Olaguibel J, Rial M, Quirce S, Arismendi E, Barranco P, Betancor D, Bobolea , Cardaba B, Carmona MC,**

- Curto E, Domínguez-Ortega J, González-Barcala F, Martínez-Rivera C, Mahillo-Fernández , Muñoz X, Picado C, Plaza , Muñoz JR, Retes LS, Valero A, Delpozo , Mullol J, Sastre J.** Reply to olfactory function and biologic treatments: a comment on available real-life studies. *J Invest Allerg Clin.* 2023; 33(6): 503-4. Letter. IF: 6.1; Q1
- **Barroso B, Valverde-Monge M, Alobid , Olaguibel JM, Rial MJ, Quirce S, Arismendi E, Barranco P, Betancor D, Bobolea , Cardaba B, Carmona MC, Curto E, Domínguez-Ortega J, González-Barcala FJ, Martínez-Rivera C, Mahillo-Fernández , Muñoz X, Picado C, Plaza , Muñoz JMR, Soto-Retes L, Valero A, del Pozo , Mullol J, Sastre J.** Improvement in olfaction in patients with CRSwNP and severe asthma taking anti-IgE and anti-IL-5 biologics: a real-life study. *J Invest Allerg Clin.* 2023; 33(1): 37-44. Article. IF: 6.1; Q1
- **Betancor C, Olaguibel JM, Rodrigo-Muñoz JM, Puebla MJA, Arismendi E, Barranco P, Barroso B, Bobolea , Cardaba B, Cruz MJ, Curto E, Del Pozo , Domínguez-Ortega J, González-Barcala FJ, Luna-Porta JA, Martínez-Rivera C, Mullol J, Muñoz X, Picado C, Plaza , Quirce S, Rial MJ, Soto-Retes L, Valero A, Valverde-Monge M, Sastre J.** Lung function abnormalities and their correlation with clinical characteristics and inflammatory markers in adult asthma. *J Invest Allerg Clin.* 2023; 33(4): 294-6. Editorial Material. IF: 6.1; Q1
- **Betancor D, Villalobos-Vilda C, Olaguibel JM, Rodrigo-Muñoz JM, Puebla MJA, Arismendi E, Barranco P, Barroso B, Bobolea I, Cardaba B, Cruz MJ, Curto E, Del Pozo V, Domínguez-Ortega J, González-Barcala FJ, Luna-Porta JA, Martínez-Rivera C, Mullol J, Muñoz X, Picado C, Plaza V, Quirce S, Rial MJ, Soto-Retes L, Valero A, Valverde-Monge M, Sastre J.** The New ERS/ATS 2022 Bronchodilator response recommendation: comparison with the previous version in an asthma cohort. *Arch Bronconeumol.* 2023; 59(9): 608-11. Letter. IF: 8.7; D1
- **Blanco-Aparicio M, Domínguez-Ortega J, Cisneros C, Colás C, Casas F, del Cuvillo A, Alobid I, Quirce S, Mullol J.** Consensus on the management of united airways disease with type 2 inflammation: a multidisciplinary Delphi study. *Allergy Asthma Clin Immunol.* 2023; 19(1): 34. Article. IF: 2.6; Q2
- **Bousquet J, Anto JM, Sousa-Pinto B, Czarlewski W, Bedbrook A, Haahela T, Klimek L, Pfaar O,**

- Kuna P, Kupczyk M, Regateiro FS, Samolinski B, Valiulis A, Yorgancioglu A, Arnavielhe S, Basagaña X, Bergmann KC, Bosnic-Anticevich S, Brussino L, Canonica GW, Cardona V, Cecchi L, Chaves-Loureiro C, Costa E, Cruz AA, Gemicioğlu B, Fokkens WJ, Ivancevich JC, Kraxner H, Kvedariene V, Larenas-Linnemann DE, Laune D, Louis R, Makris M, Maurer M, Melén E, Micheli Y, Morais-Almeida M, Mullol J, Niedozytko M, Okamoto Y, Papadopoulos NG, Patella V, Pham-Thi N, Rouadi PW, Sastre J, Scichilone N, Sheikh A, Sofiev M, Taborda-Barata L, Toppila-Salmi S, Tsiligianni I, Valovirta E, Ventura MT, Vieira RJ, Zidarn M, Amaral R, Anotegui IJ, Bédard A, Benveniste S, Bewick M, Bindslev-Jensen C, Blain H, Bonini M, Bourret R, Braidó F, Carreiro-Martins P, Charpin D, Cherrez-Ojeda I, Chivato T, Chu DK, Cingi C, Del Giacco S, de Blay F, Devillier P, De Vries G, Doulaptsi M, Doyen V, Dray G, Fontaine JF, Gómez RM, Hagemann J, Heffler E, Hofmann M, Jassem E, Jutel M, Keil T, Kritikos V, Kull I, Kulus M, Lourenço O, Mathieu-Dupas E, Menditto E, Mösges R, Murray R, Nadif R, Neffen H, Nicola S, O'Hehir R, Olze H, Palamarchuk Y, Pepin JL, Pétré B, Picard R, Pitsios C, Puggioni F, Quirce S, Raciborski F, Reitsma S, Roche N, Rodríguez-González M, Romantowski J, Sa-Sousa A, Serpa FS, Savouré M, Shamji MH, Sova M, Sperl A, Stellato C, Todo-Bom A, Tomazic PV, Vandenplas O, Van Eerd M, Vasankari T, Viart F, Wasserman S, Fonseca JA, Zuberbier T.** Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air® approach. *Clin Transl Allergy.* 2023; 13(1): e12215. Article. IF: 4.6; Q2
- **Bousquet J, Shamji MH, Anto JM, Schünemann HJ, Canonica GW, Jutel M, Del Giacco S, Zuberbier T, Pfaar O, Fonseca JA, Sousa-Pinto B, Klimek L, Czarlewski W, Bedbrook A, Amaral R, Anotegui IJ, Bosnic-Anticevich S, Braidó F, Loureiro CC, Gemicioğlu B, Haahela T, Kulus M, Kuna P, Kupczyk M, Matricardi PM, Regateiro FS, Samolinski B, Sofiev M, Toppila-Salmi S, Valiulis A, Ventura MT, Barbara C, Bergmann KC, Bewick M, Blain H, Bonini M, Boulet LP, Bourret R, Brusselle G, Brussino L, Buhl R, Cardona V, Casale T, Cecchi L, Charpin D, Cherrez-Ojeda I, Chu DK, Cingi C, Costa EM, Cruz AA, Devillier P, Dramburg S, Fokkens WJ, Gotua M, Heffler E, Ispayeva Z, Ivancevich JC, Joos G, Kaidashev I, Kraxner H, Kvedariene V, Lar-**

- enas-Linnemann DE, Laune D, Lourenço O, Louis R, Makela M, Makris M, Maurer M, Melén E, Micheli Y, Morais-Almeida M, Mullol J, Niedozytko M, O'Hehir R, Okamoto Y, Olze H, Papadopoulos NG, Papi A, Patella V, Pétré B, Pham-Thi N, Puggioni F, Quirce S, Roche N, Rouadi PW, Sa-Sousa A, Sagara H, Sastre J, Scichilone N, Sheikh A, Sova M, Ulrik CS, Taborda-Barata L, Todo-Bom A, Torres MJ, Tsiligianni I, Usmani OS, Valovirta E, Vasankari T, Vieira RJ, Wallace D, Wasserman S, Zidarn M, Yorgancioglu A, Zhang L, Chivato T, Ollert M.** Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report. *Allergy.* 2023; 78(7): 1758-76. Review. IF: 12.6; D1
- **Bousquet J, Melén E, Haahela T, Koppelman GH, Togias A, Valenta R, Akdis CA, Czarlewski W, Rothenberg M, Valiulis A, Wickman M, Akdis M, Aguilar D, Bedbrook A, Bindslev-Jensen C, Bosnic-Anticevich S, Boulet LP, Brightling CE, Brussino L, Burte E, Bustamante M, Canonica GW, Cecchi L, Celedon JC, Loureiro CC, Costa E, Cruz AA, Erhola M, Gemicioğlu B, Fokkens WJ, García-Aymerich J, Guerra S, Heinrich J, Ivancevich JC, Keil T, Klimek L, Kuna P, Kupczyk M, Kvedariene V, Larenas-Linnemann DE, Lemonnier N, Carlsen KCL, Louis R, Makela M, Makris M, Maurer M, Momas I, Morais-Almeida M, Mullol J, Naclerio RN, Nadeau K, Nadif R, Niedozytko M, Okamoto Y, Ollert M, Papadopoulos NG, Pas-salacqua G, Patella V, Pawankar R, Pham-Thi N, Pfaar O, Regateiro FS, Ring J, Rouadi PW, Samolinski B, Sastre J, Savouré M, Scichilone N, Shamji MH, Sheikh A, Siroux V, Sousa-Pinto B, Standl M, Sunyer J, Taborda-Barata L, Toppila-Salmi S, Torres MJ, Tsiligianni I, Valovirta E, Vandenplas O, Ventura MT, Weiss S, Yorgancioglu A, Zhang L, Latiff AHA, Aberer W, Agache I, Al-Ahmad M, Alobid I, Anotegui IJ, Arshad SH, Asayag E, Barbara C, Baharudin A, Battur L, Bennoor KS, Bergheda EC, Bergmann KC, Bernstein D, Bewick M, Blain H, Bonini M, Braidó F, Buhl R, Bumbacea RS, Bush A, Calderon M, Calvo-Gil M, Camargos P, Caraballo L, Cardona V, Carr W, Carreiro-Martins P, Casale T, Casale A, Chandra Sekhharan R, Charpin D, Chen YZ, Cherrez-Ojeda I, Chivato T, Chkhartishvili E, Christoff G, Chu DK, Cingi C, de Sousa JC, Corrigan C, Custovic A, D'Amato G, Del Giacco S, De Blay F, Devillier P, Didier A, Teixeira**



3. Information groups by area

3.4 Large System Pathologies Area

- MD, Dokic D, Douagui H, Doulapsi M, Durham S, Dykewicz M, Eiwegger T, El-Sayed ZA, Emuzyte R, Fiocchi A, Fyhrquist N, Gómez RM, Gotua M, Guzman MA, Hagemann J, Hamamah S, Halken S, Halpin DMG, Hofmann M, Hossny E, Hrubisko M, Irani C, Ispayeva Z, Jares E, Jartti T, Jassem E, Julge K, Just J, Jutel M, Kaidashev I, Kalayci O, Kalyoncu AF, Kardas P, Kirenga B, Kraxner H, Kull I, Kulus M, La Grutta S, Lau S, Thi LL, Levin M, Lipworth B, Lourenço O, Mahboub B, Martínez-Infante E, Matricardi P, Miculinic N, Miguères N, Mihaltn F, Mohammad Y, Moniuszko M, Montefort S, Neffen H, Nekam K, Nunes E, Tshipukane DN, O'Hehir R, Ogulur I, Ohta K, Okubo K, Ouedraogo S, Olze H, Pali-Schöll J, Palomares O, Palosuo K, Panaitescu C, Panzner P, Park HS, Pit-sios C, Plavec D, Popov TA, Puggioni F, Quirce S, Recto M, Repka-Ramírez MS, Cordeiro CR, Roche N, Rodríguez-González M, Romantowski J, Rosario N, Rottem M, Sagara H, Serpa FS, Sayah Z, Scheire S, Schmid-Grendelmeier P, Sisul JC, Sole D, Soto-Martínez M, Sovia M, Sperl A, Spranger O, Stelmach R, Ulrik CS, Thomas M, To T, Todo-Bom A, Tomazic PV, Urrutia-Pereira M, Valentin-Rostan M, Van Ganse E, van Hage M, Vasankari T, Vichyanond P, Vieggi G, Wallace D, Wang DY, Williams S, Worm M, Yiallouris P, Yusuf O, Zaitoun F, Zernotti M, Zidarn M, Zuberbier J, Fonseca JA, Zuberbier T, Anto JM. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis. *Allergy*. 2023; 78(5): 1169-203. Review. IF: 12.6; D1
- **Brusselle G, Quirce S, Papi A, Kuna P, Chipps BE, Hanania NA, Blaiss M, Msihid J, Jacob-Nara JA, Deniz Y, Rowe PJ, Gall R, Ortiz B, Djandji M, Radwan A.** Dupilumab efficacy in patients with uncontrolled or oral corticosteroid-dependent allergic and nonallergic asthma. *J Allergy Clin Immunol Pract*. 2023; 11(3): 873-84. Article. IF: 8.2; Q1
 - **Caballero T, Leonart-Bellfill R, Pedrosa M, Ferrer L, Guilarte M.** Expert review and consensus on the treat-to-target management of hereditary angioedema: from scientific evidence to clinical practice. *J Invest Allerg Clin*. 2023; 33(4): 238-49. Review. IF: 6.1; Q1
 - **Cabanillas B, Murdaca G, Guemari A, Torres MJ, Azkur AK, Aksoy E, Vitte J, de las Vecillas L, Giovannini M, Fernández-Santamaría R, Castagnoli R, Orsi A, Amato R, Giberti I, Catala A, Ambroze D, Schaub B, Tramper-Stranders GA, Novak N, Nadeau KC, Agache I, Akdis M, Akdis CA.** A compilation answering 50 questions on Monkeypox virus and the current Monkeypox outbreak. *Allergy*. 2023; 78(3): 639-62. Review. IF: 12.6; D1
 - **Crespo-Lessmann A, Marqués-Espi JA, Domínguez-Ortega J, Llano LPD, Blanco-Aparicio M, Santana M, Palop-Cervera M, Álvarez EJ, Fraj J.** Quality indicators in the rational management of severe asthma: A Spanish multidisciplinary consensus. *J Healthc Qual Res*. 2023; 38(5): 277-83. Article. IF: 1.1; Q4
 - **Dávila I, Puente L, Quirce S, Arismendi E, Díaz-Palacios M, Pereira-Vega A, de Diego A, Rodríguez-Hermosa JL, Cea-Calvo L, Sánchez-Jariego M, López-Cotarello P, Domingo C.** Characteristics and management of patients with refractory or unexplained chronic cough in outpatient hospital clinics in Spain: a retrospective multicenter study. *Lung*. 2023; 201(3): 275-86. Article. IF: 4.6; Q1
 - **de las Vecillas L, Caimmi D, Isabwé GAC, Madrigal-Burgaleta R, Soyer O, Tanno L, Vultaggio A, Giovannini M, Mori F.** Hypersensitivity reactions to biologics in children. *Expert Opin Biol Ther*. 2023; 23(1): 61-72. Review. IF: 3.6; Q2
 - **de las Vecillas L, Quirce S.** Landscape of short-acting beta-agonists (SABA) overuse in Europe. *Clin Exp Allergy*. 2023; 53(2): 132-44. Review. IF: 6.3; Q1
 - **de Llano LP, Moragón EM, Entrenas LM, Rivera CM, Cisneros C, Blanco-Aparicio M, Trisán A, Plaza V, Ramos J, Fitas EF, Sánchez-Covisa J, Domínguez-Ortega J.** Validation of the asthma impairment and risk questionnaire in Spain: a useful tool for assessing asthma control in adolescents and adults. *J Invest Allerg Clin*. 2023; 33(5): 397-400. Editorial Material. IF: 6.1; Q1
 - **Delgado J, Navarro A, Álvarez-Gutiérrez EJ, Cisneros C, Domínguez-Ortega J.** Unmet Needs in Severe Allergic Asthma. *Open Respir Arch*. 2023; 5(4): 100282. Article. Not indexed
 - **Diamant Z, Jesenak M, Hanania NA, Heaney LG, Djukanovic R, Ryan D, Quirce S, Backer V, Gaga M, Pavord I, Antolin-Américo D, Assaf S, Bakakos P, Bobcokova A, Busse W, Kappen J, Loukides S, van Maaren M, Panzner P, Pite H, Spanevello A, Stenberg H, Striz I, Thio B, Vasakova MK, Conti D, Fokkens W, Lau S, Scadding GK, Van Staeyen E, Hellings PW, Bjerrmer L.** EUFOREA pocket guide on the diagnosis and management of asthma: An educational and practical tool for general practitioners, non-respiratory physicians, paramedics and patients. *Resp Med*. 2023; 218: 107361. Letter. IF: 3.5; Q2
 - **Domínguez-Ortega J, Luna-Porta J, Olaguibel JM, Barranco P, Arismendi E, Barroso B, Betancor D, Bobolea I, Caballero ML, Cárdena B, Cruz MJ, Curto E, González-Barcala EJ, Losantos-García I, Martínez-Rivera C, Méndez-Brea P, Mullol J, Muñoz X, Picado C, Plaza V, del Pozo V, Rial MJ, Sastre J, Soto L, Valero A, Valverde-Monge M, Quirce S.** Exacerbations among patients with asthma are largely dependent on the presence of multimorbidity. *J Invest Allerg Clin*. 2023; 33(4): 281-8. Article. IF: 6.1; Q1
 - **Domínguez-Ortega J, Plaza V, Nieto A, Romero JD, Ancochea J, Mejía N, Pastor M, Blanco-Aparicio M.** The ATLAS ASMA Study: Assessing the impact of asthma on patients' life-the Spanish patients' perspective. *J Asthma Allergy*. 2023; 16: 461-71. Article. IF: 3.7; Q2
 - **Dramburg S, Hilger C, Santos AF, de las Vecillas L, Aalberse RC, Acevedo N, Aglas L, Altmann F, Arruda KL, Asero R, Ballmer-Weber B, Barber D, Beyer K, Biedermann T, Bilo MB, Blank S, Bosshard PP, Breiteneder H, Brough HA, Bublin M, Campbell D, Caraballo L, Caubet JC, Celi G, Chapman MD, Chruszcz M, Custovic A, Czolk R, Davies J, Douladiris N, Eberlein B, Ebisawa M, Ehlers A, Eigemann P, Gadermaier G, Giovannini M, Gómez F, Grohman R, Guillet C, Hafner C, Hamilton RG, Hauser M, Hawranek T, Hoffmann HJ, Holzhauser T, Iizuka T, Jacquet A, Jakob T, Janssen-Weets B, Jappe U, Jutel M, Kalic T, Kamath S, Kespohl S, Kleine-Tebbe J, Knol E, Knulst A, Konradsen JR, Korosec P, Kuehn A, Lack G, Le TM, Lopata A, Luenzo O, Mäkelä M, Marra AM, Mills C, Morisset M, Muraro A, Nowak-Węgrzyn A, Nugraha R, Ollert M, Palosuo K, Pastorello EA, Patil SU, Platts-Mills T, Pomés A, Poncet P, Potapova E, Poulsen LK, Radauer C, Radulovic S, Raulf M, Rougé P, Sastre J, Sato S, Scala E, Schmid JM, Schmid-Grendelmeier P, Schrama D, Sénéchal H, Traidl-Hoffmann C, Valverde-Monge M, van Hage M, van Ree R, Verhoeckx K, Vieths S, Wickman M, Zakzuk J, Matricardi PM, Hoffmann-Sommergruber K.** EAACI molecular allergology user's guide 2.0. *Pediatr Allerg Immun-Uk*. 2023; 34: e13854. Article. IF: 4.3; Q2
 - **Entrala A, Domínguez-Ortega J, Lucas EP, Losantos I, Lluch-Bernal M, Quirce S, Rodríguez-Pérez R.** Lymphocyte transformation test in the diagnosis of adult fish-induced enterocolitis syndrome. *J Allergy Clin Immunol Pract*. 2023; 11(9): 2945-7. Letter. IF: 8.2; Q1
 - **Gall XM, Domínguez-Ortega J, Pascual S, López CC, Resler G, Nuevo J, Monteagudo G.** Clinical burden related to oral corticosteroid treatment of severe asthma in Spain: LEVANTE study. *J Asthma*. 2023; 60(5): 890-9. Article. IF: 1.7; Q3
 - **García-Abujeta JL, Iriarte P, Gonzalo-Garijo MA, de las Vecillas L, Bernaola M.** Use of epicutaneous tests in the study of drug allergy. *curr treat options allergy*. 2023; 10(3): 283-300. Review. IF: 1.9; Q3
 - **Gil-Martínez M, Lorente-Sorolla C, Rodríguez-Muñoz JM, Lendínez MA, Núñez-Moreno G, de la Fuente L, Mínguez P, Mahillo-Fernández I, Sastre J, Valverde-Monge M, Quirce S, Caballero ML, González-Barcala EJ, Arismendi E, Bobolea I, Valero A, Muñoz X, Cruz MJ, Martínez-Rivera C, Plaza V, Olaguibel JM, del Pozo V.** Analysis of differentially expressed microRNAs in serum and lung tissues from individuals with severe asthma treated with oral glucocorticoids. *Int J Mol Sci*. 2023; 24(2): 1611. Article. IF: 4.9; Q1
 - **Gil-Martínez M, Lorente-Sorolla C, Rodríguez-Muñoz JM, Naharro S, García-de Castro Z, Sastre J, Valverde-Monge M, Quirce S, Caballero ML, Olaguibel JM, del Pozo V.** Obese asthma phenotype is associated with hsa-mir-26a-1-3p and hsa-mir-376a-3p modulating the IGF axis. *Int J Mol Sci*. 2023; 24(14): 11620. Article. IF: 4.9; Q1
 - **Hilger C, Dramburg S, Santos AF, de las Vecillas L, Hoffmann-Sommergruber K.** The Handbook of Molecular Allergy 2.0: Update on relevant new content. *Allergo J*. 2023; 32(7): 18-28. Article. IF: 1.1; Q4
 - **Laorden D, Domínguez-Ortega J, Carpio C, Barranco P, Villamañán E, Romero D, Quirce S, Álvarez-Sala R.** Long COVID outcomes in an asthmatic cohort and its implications for asthma control. *Resp Med*. 2023; 207: 107092. Article. IF: 3.5; Q2
 - **Laorden D, Zamarrón E, Romero D, Domínguez-Ortega J, Villamañán E, Losantos I, Gayá F, Quirce S, Álvarez-Sala R.** Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R. *Resp Med*. 2023; 211: 107216. Article. IF: 3.5; Q2
 - **Llano LP, Cisneros C, Domínguez-Ortega J, Martínez-Moragón E, Olaguibel JM, Plaza V,**



3.4 Large System Pathologies Area

Quirce S, Dávila. Response to monoclonal antibodies in asthma: definitions, potential reasons for failure, and therapeutic options for suboptimal response. *J Invest Allerg Clin.* 2023; 33(1): 1-13. Review. IF: 6.1; Q1

- Lozano-Espinosa M, Antolín-Amérigo D, Riera J, Vidal FG, Quirce S, Rodríguez JA. Extracorporeal membrane oxygenation (ECMO) and beyond in near fatal asthma: A comprehensive review. *Resp Med.* 2023; 215: 107246. Review. IF: 3.5; Q2
- Marqués-Mejías MA, Tomás-Pérez M, Hernández-Martin , Loli-Ausejo D, Quirce S. Recurrent bronchospasm in children treated in the emergency department. *J Invest Allerg Clin.* 2023; 33(1): 49-51. Editorial Material. IF: 6.1; Q1
- Matabuena M, Salgado EJ, Nieto-Fontarigo JJ, Álvarez-Puebla MJ, Arismendi E, Barranco P, Bobolea I, Caballero ML, Cañas JA, Cárdena B, Cruz MJ, Curto E, Domínguez-Ortega J, Luna JA, Martínez-Rivera C, Mullol J, Muñoz X, Rodríguez-García J, Olaguibel JM, Picado C, Plaza V, Quirce S, Rial MJ, Romero-Mesones C, Sastre B, Soto-Retes L, Valero A, Valverde-Monge M, Del Pozo V, Sastre J, González-Barcala FJ. Identification of asthma phenotypes in the spanish mega cohort study using cluster analysis. *Arch Bronconeumol.* 2023; 59(4): 223-31. Article. IF: 8.7; D1
- Miguera N, Vandenplas O, Walusiak-Skorupa J, Munoz X, Suojalehto H, van Kampen V, Mason P, Quirce S, de Blay F. Work-related dysphonia in subjects with occupational asthma is associated with neutrophilic airway inflammation. *Clin Transl Allergy.* 2023; 13(5): e12218. Letter. IF: 4.6; Q2
- Moreno CM, Sánchez CA, Conejero DB, Quirce S, Gutiérrez FJA, Cardona , Sánchez-Herrero MG, PAGE Study Grp. Understanding severe asthma through small and big data in spanish hospitals: The PAGE Study. *J Invest Allerg Clin.* 2023; 33(5): 373-82. Article. IF: 6.1; Q1
- Narváez-Fernández EJ, Entrala A, Nin-Valencia A, Mir-Ihara P, Losantos-García I, Domínguez-Ortega J, González-Fernández MA, Quirce S, Hernández-Cano N, Cabañas R, Caballero T. Long-term omalizumab in elderly patients with chronic urticaria: is it a safe therapy?. *Int Arch Allergy Imm.* 2023; 184(10): 1003-9. Article. IF: 2.5; Q3
- Nin-Valencia A, Domínguez-Ortega J, Cabañas R, Sánchez H, Fiandor A, Lluch M, Ramírez E, Gómez-Traseira C, Rodríguez A, González-Muñoz M.

The lymphocyte transformation test in delayed hypersensitivity reactions induced by ibuprofen and/or metamizole. *J Invest Allerg Clin.* 2023; 33(1): 52-53. Editorial Material. IF: 6.1; Q1

- Nin-Valencia A, Fiandor A, Lluch M, Quirce S, Caballero T, Heredia RR, González-Muñoz M, Caballero ML, Cabañas R. Safe administration of SARS-CoV-2 vaccine after desensitization to a biologic containing polysorbate 80 in a patient with polyethylene glycol-induced severe anaphylaxis and sensitization to polysorbate 80. *J Invest Allerg Clin.* 2023; 33(2): 151-3. Article. IF: 6.1; Q1
- Plaza Moral V, Alobid I, Álvarez Rodríguez C, Blanco Aparicio M, Ferreira J, García G, Gómez-Outes A, Garín Escrivá N, Gómez Ruiz F, Hidalgo Requena A, Korta Murua J, Molina Paris J, Pellegrini Belinchon FJ, Plaza Zamora J, Praena Crespo M, Quirce Gancedo S, Sanz Ortega J, Soto Campos JG. GEMA 5.3. Spanish Guideline on the Management of Asthma. *Open Respir Arch.* 2023; 5(4): 100277. Article. Not indexed
- Plaza V, Domínguez-Ortega J, Alsina DGS, Lo Re D, Sicras-Mainar A. Comprehensive observational study in a large cohort of asthma patients after adding LAMA to ICS/LABA. *Pharmaceuticals (Basel).* 2023; 16(11): 1609. Article. IF: 4.3; Q2
- Pontone M, Giovannini M, Barni S, Mori F, Venturini E, Galli L, Valleriani C, Vecillas LD, Sackesen C, Lopata AL, Buyuktiryaki B. IgE-mediated Anisakis allergy in children. *Allergol Immunopath.* 2023; 51(1): 98-109. Review. IF: 2.5; Q3
- Pose K, Laorden D, Hernández N, Villamañán E, Quirce S, Domínguez-Ortega J. Efficacy of dupilumab for severe atopic dermatitis co-occurring with asthma in a real-world setting. *J Invest Allerg Clin.* 2023; 33(3): 217-9. Editorial Material. IF: 6.1; Q1
- Puente-Maestu L, Dávila I, Quirce S, Crespo-Lessmann A, Martínez-Moragón E, Sola J, Nieto ML, González-Barcala FJ, Cea-Calvo L, Sánchez-Jareño M, Rivas-Pardinas C, Domingo C. Burden of refractory and unexplained chronic cough on patients' lives: a cohort study. *ERJ Open Res.* 2023; 9(5): 00425-2023. Article. IF: 4.3; Q1
- Quirce S, Cosío BG, España A, Blanco R, Mullol J, Santander C, del Pozo V. Management of eosinophil-associated inflammatory diseases: the importance of a multidisciplinary approach. *Front Immunol.* 2023; 14: 1192284. Article. IF: 5.7; Q1

- Quirce S, Trigueros JA, Ausín P, Cano RM, Hernández MR, González-Barcala FJ, Campos JGS, Galo AP, Serrano CC, Domínguez-Ortega J, Bastida AP, Erquicia SP, Dávila , Moragón EM, Zamora FJP, Barbero FS, Plaza. Role of different health care professionals in the management of asthma patients: The GEMA-FORUM IV Task Force. *J Invest Allerg Clin.* 2023; 33(3): 214-7. Editorial Material. IF: 6.1; Q1
- Rodríguez-Pérez R, de las Vecillas L, Cabañas R, Bellón T. Tools for etiologic diagnosis of drug-induced allergic conditions. *Int J Mol Sci.* 2023; 24(16): 12577. Review. IF: 4.9; Q1
- Román-Carrasco P, Klug C, Hemmer W, Focke-Tejkl M, Raith M, Grosinger I, Stoll P, Quirce S, Sánchez-Jareño M, Martínez-Blanco M, Molina E, Somoza V, Lieder B, Marin Z, Noebauer K, Hummel K, Razzazi-Fazeli E, Swoboda I. Bos d 13, A Novel heat-stable beef allergen. *Mol Nutr Food Res.* 2023; 67(16): e2200601. Article. IF: 4.5; Q1
- Romero-Mesones C, Cruz MJ, Alobid I, Barroso B, Arismendi E, Barranco P, Betancor D, Bobolea I, Cárdena B, Curto E, Domenech G, Domínguez-Ortega J, Espejo D, González-Barcala FJ, Luna-Porta JA, Martínez-Rivera C, Mendez-Brea P, Mullol J, Olaguibel JM, Picado C, Plaza V, del Pozo V, Quirce S, Rial MJ, Rodrigo-Muñoz JM, Sastre J, Serrano S, Soto-Retes L, Valero A, Valverde-Monge M, Munoz X. Disposition of Work-Related Asthma in a Spanish Asthma Cohort: Comparison of Asthma Severity Between Employed and Retired Workers. *J Allergy Clin Immunol Pract.* 2023; 11(11): 3407-41. Article. IF: 8.2; Q1
- Sánchez CA, Blanco-Aparicio M, Domínguez-Ortega J, Donaire JG, París JM, Marcos NS, Plaza. Validation of the algorithm for the monitoring and control of asthma through telemedicine: The COMETA Project. *J Invest Allerg Clin.* 2023; 33(3): 223-5. Editorial Material. IF: 6.1; Q1
- Tomás-Pérez M, Vecillas LD. Allergy to rivaroxaban: a case report showing cross-reactivity with other direct anticoagulants and the role of the basophil activation test. *J Invest Allerg Clin.* 2023; 33(5): 405-6. Editorial Material. IF: 6.1; Q1
- Vilchez-Sánchez F, Rodríguez-Pérez R, Gómez-Traseira C, Domínguez-Ortega J, Hernández-Rivas L, García IL, Quirce S, Pedrosa M. Sensitisation to peach allergen Pru p 7 is associated with severe clinical symptoms in a Spanish population. *Pediatr Allerg Immun-Uk.* 2023; 34(9): e14030. Article. IF: 4.3; Q2

Research projects

- Caballero Molina MT. Desarrollar las tareas necesarias para poner en marcha el proyecto angiocare 2021. Ediciones Mayo S.A. 2022-Ongoing. *Managment centre: FIBHULP*
- Caballero Molina MT. Development and trans-cultural validation of an international specific questionnaire (IHAE-QOL) for assessment of health related quality of life in adult patients with hereditary angioedema due to c1 inhibitor deficiency (HAE) and quality of life study (DTV-IHAE-QOL). Hereditary Angio-Edema In. 2009-Ongoing. *Managment centre: FIBHULP*
- Caballero Molina MT. Estudio de las características clínicas y fisiopatológicas del angioedema sin habones (PI19/01434). ISCIII. 2020-2024. *Managment centre: FIBHULP*
- Caballero Molina MT. Impacto humanístico y económico del angioedema hereditario en España. Estudio Impactaeh. Shire International GmbH. 2021-Ongoing. *Managment centre: FIBHULP*
- de las Vecillas Sánchez L. Estudio de la inmunomodulación celular inducida en las desensibilizaciones a quimioterápicos tras reacciones inmediatas y tardías. Fundación de la Sociedad Española de Alergología e Inmunología Clínica. 2022-Ongoing. *Managment centre: FIBHULP*
- Domínguez Ortega FJ. Asesoramiento para el diseño del estudio clínico Ensayo clínico prospectivo multicéntrico aleatorizado de doble simulación controlado con placebo de búsqueda de la dosis más eficaz para el tratamiento de rinitis/rinoconjuntivitis por alergia frente al polen gramíneas. Immunotek. 2015-Ongoing. *Managment centre: FIBHULP*
- Domínguez Ortega FJ. Estudio de coste-efectividad de mepolizumab en pacientes con asma grave no controlada en condiciones de vida-real. Glaxosmithkline S. A. 2021-Ongoing. *Managment centre: FIBHULP*
- Quirce Gancedo SE. Integra: utilidad de los ratios en el diagnóstico alergológico: de la investigación a la práctica clínica. Thermo Fisher Diagnostics S.L.U. 2022-Ongoing. *Managment centre: FIBHULP*



- **Quirce Gancedo SE.** Relación entre asma y obesidad en la población española mayor o igual a 18 años. Novartis Farmaceutica S.A. 2009-Ongoing. *Managment centre: FIBHULP*
- **Quirce Gancedo SE.** Sesiones en investigación del diagnóstico molecular como herramienta de identificación de perfiles de respuesta en pacientes con enfermedad respiratoria alérgica y alergia a alimentos. Thermo Fisher Diagnostics S.L.U. 2017-Ongoing. *Managment centre: FIBHULP*
- **Rodríguez Pérez MR.** Caracterización alérgica y determinación de la relevancia clínica del polen de encina como alérgeno de interés en pacientes policlínicos y su relación con el desarrollo de síndrome de alergia oral con alimentos (PI22/00221). ISCIII. 2023-2025. *Managment centre: FIBHULP*
- **Rodríguez Pérez MR.** Evaluación de la capacidad alérgica de productos alimentarios mediante test de activación de basófilos y sensibilización cutánea con alimentos. Angulas Aguinaga S. A. U. 2018-Ongoing. *Managment centre: FIBHULP*
- **Tomás Pérez M.** Efectividad de la inmunoterapia sublingual de ltp (slit melocoton) en pacientes con alergia a melocoton y otros vegetales por

sensibilización a ltp en condiciones de práctica clínica habitual. Alk-Abello S.A. 2020-Ongoing. *Managment centre: FIBHULP*

Cibers and Retics

- **CB06/07/1033 Caballero Molina MT.** Centro de Investigación en Red de Enfermedades Respiratorias. (CIBERER). ISCIII. (31/12/2023). FIBHULP

Clinical trials

- **Caballero Molina MT.** Ensayo de extensión abierto para evaluar la seguridad a largo plazo de kvd900, un inhibidor oral de la caliceína plasmática, para el tratamiento a demanda de las crisis de angioedema en pacientes adolescentes y adultos con angioedema hereditario de tipo i o ii. *Type/Phase: III*
Sponsored by: Kalvista Pharmaceuticals, Ltd
Signed date: 12/06/2023
- **Caballero Molina MT.** Ensayo de fase 3, aleatorizado, doble ciego, controlado con placebo y con tres grupos cruzados, para evaluar la eficacia y la seguridad de dos niveles de dosis de kvd900, un inhibidor oral de la caliceína plasmática, para el

tratamiento a demanda de las crisis de angioedema en pacientes adolescentes y adultos con angioedema hereditario de tipo i o ii.

Type/Phase: III
Sponsored by: Kalvista Pharmaceuticals, Ltd
Signed date: 08/05/2023

- **Caballero Molina MT.** Estudio de fase 1/2, abierto y de aumento escalonado de la dosis para determinar la seguridad, la tolerabilidad y la eficacia de bmn 331, un gen de transferencia de serping1 humano mediada por el vector del virus adenoasociado (aav), en pacientes con angi. *Type/Phase: I*
Sponsored by: Biomarin Pharmaceutical, Inc
Signed date: 07/06/2023
- **Caballero Molina MT.** Estudio sin enmascaramiento a largo plazo para evaluar la seguridad y la eficacia de donidorsén como tratamiento profiláctico del angioedema hereditario (aeh). *Type/Phase: III*
Sponsored by: Ionis Pharmaceuticals Inc
Signed date: 31/10/2023

- **Domínguez Ortega FJ.** Estudio observacional, retrospectivo, multicéntrico, para recoger datos en vida real de la seguridad y efectividad de la inmunoterapia con alérgenos administrada en los últimos 5 años a pacientes con asma grave. *Type/Phase: EPA-SP*
Sponsored by: Fundacion De La Sociedad Espanola De Alergología E Inmunología Clínica (Seac)
Signed date: 13/01/2023

- **Phillips Anglés E.** Estudio en fase III para evaluar la seguridad y farmacocinética de la profilaxis con berotralstat en niños de 2 a <12 años con angioedema hereditario. *Type/Phase: III*
Sponsored by: Biocryst Pharmaceuticals Inc
Signed date: 14/12/2023

- **Tomás Pérez M.** Estudio de extensión de fase 3 en régimen abierto, multicéntrico e internacional para evaluar la seguridad a largo plazo de cc-93538 en sujetos adultos y adolescentes con esofagitis eosinofílica.

3. Information groups by area

3.4 Large System Pathologies Area

Type/Phase: III
Sponsored by: Celgene International li-Sarl
Signed date: 06/09/2023

- **Tomás Pérez M.** Estudio observacional prospectivo para evaluar la seguridad de "modigoid®" y "modigoid plus®" en pacientes mono o polialérgicos con rinitis/rinoconjuntivitis alérgica, con o sin asma asociada. *Type/Phase: EPA-SP*
Sponsored by: Roxall Medicina España, S.A(Bial Industrial Farmaceutica, S.A.)
Signed date: 415/02/2023

Patents and trademarks

- **Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee.** Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.
- **Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee.** Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.

HAE-QoL
 HEREDITARY ANGIOEDEMA QUALITY OF LIFE

- **Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees.** Food allergen extracts and methods of producing and using the same. EP16382413.9 (Publication Number pending); 2016 September 06.
- **del Pozo Abejón V, Sastre Domínguez J, Rodrigo-Muñoz JM, Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA, inventors; FIBHULP, Centro de Investigación Biomédica en Red (CIBER), FIBHULP, Fundación Conchita Rábago de Jiménez Díaz, assignees.** In vitro method for identifying severity levels in bronchial asthma patients. P201730739; 2017 May 29.